Profile data is unavailable for this security.
About the company
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
- Revenue in USD (TTM)465.22m
- Net income in USD-13.39m
- Incorporated2018
- Employees869.00
- LocationOrganogenesis Holdings Inc85 Dan RdCANTON 02021-2810United StatesUSA
- Phone+1 (781) 575-0775
- Fax+1 (302) 655-5049
- Websitehttps://investors.organogenesis.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 432.24m | 27.00 | -- | 8.37 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 432.76m | 73.00 | -- | 2.37 | -- | 11.64 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Vanda Pharmaceuticals Inc. | 212.07m | -84.20m | 439.09m | 368.00 | -- | 0.9422 | -- | 2.07 | -1.43 | -1.43 | 3.61 | 7.89 | 0.3403 | 6.46 | 4.55 | 576,288.10 | -13.51 | 1.56 | -16.20 | 1.80 | 94.44 | 91.45 | -39.70 | 3.99 | 3.10 | -- | 0.011 | 0.00 | 3.18 | -2.64 | -853.29 | -- | -13.62 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 461.24m | 30.00 | -- | 3.76 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Ocugen Inc | 5.37m | -64.02m | 462.32m | 95.00 | -- | 124.65 | -- | 86.09 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 471.82m | 227.00 | -- | 1.17 | -- | 3,931.86 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 477.19m | 869.00 | -- | 1.87 | 99.66 | 1.03 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 480.70m | 163.00 | -- | 1.63 | -- | 40.79 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 485.60m | 263.00 | -- | -- | -- | 6.46 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Verastem Inc | 13.38m | -241.11m | 489.16m | 78.00 | -- | -- | -- | 36.56 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 494.38m | 95.00 | -- | 3.68 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 495.58m | 72.00 | -- | 3.09 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 498.63m | 100.00 | -- | 2.29 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 517.08m | 300.00 | -- | 1.43 | -- | 12,611.65 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 519.12m | 76.00 | -- | 4.07 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 519.14m | 82.00 | 11.04 | 0.9841 | 7.88 | 2.10 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
Data as of Feb 12 2026. Currency figures normalised to Organogenesis Holdings Inc's reporting currency: US Dollar USD
43.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2025 | 12.13m | 9.56% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 11.73m | 9.24% |
| First Light Asset Management LLCas of 30 Sep 2025 | 7.50m | 5.91% |
| Assenagon Asset Management SA (Germany)as of 31 Dec 2025 | 5.54m | 4.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.40m | 3.47% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.14m | 3.27% |
| DWS Investments (UK) Ltd.as of 30 Sep 2025 | 3.28m | 2.59% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 2.75m | 2.17% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 1.75m | 1.38% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.72m | 1.36% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
